Ocular Therapeutix Financial Statements
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ocular Therapeutix revenue and earnings
In fiscal 2025, Ocular Therapeutix generated $52.0 million in revenue, down 18.5% from fiscal 2024, the first decline in the 14 years shown. Ocular Therapeutix reported a net loss of $265.9 million, compared with a loss of $193.5 million a year earlier. Gross margin was 87.3% (down from 91.2%) and operating margin -519.8%.
Diluted earnings per share came in at -$1.42. Over the last 5 fiscal years, OCUL's revenue has grown at a 24.4% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Ocular Therapeutix income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.95M | 63.72M | 58.44M | 51.49M | 43.52M | 17.40M | 4.23M | 1.99M | 1.92M | 1.89M |
| Revenue growth (YoY) | -18.47% | +9.03% | +13.49% | +18.32% | +150.08% | +311.71% | +112.41% | +3.48% | +1.91% | +7.83% |
| Cost of Revenue | 6.57M | 5.63M | 5.28M | 4.54M | 4.41M | 2.08M | 2.33M | 465.00K | 457.00K | 443.00K |
| Gross Profit | 45.38M | 58.10M | 53.16M | 46.95M | 39.12M | 15.32M | 1.90M | 1.52M | 1.47M | 1.44M |
| Operating Expenses | 315.39M | 229.88M | 135.54M | 125.61M | 117.15M | 78.17M | 87.70M | 60.64M | 63.39M | 44.77M |
| Research & Development | 197.10M | 127.64M | 61.05M | 53.46M | 50.08M | 28.69M | 41.09M | 36.91M | 30.88M | 27.07M |
| Selling, General & Admin | 118.30M | 102.24M | 74.49M | 72.15M | 67.07M | 49.47M | 46.61M | 23.73M | 32.51M | 17.70M |
| Operating Income | -270.02M | -171.78M | -82.38M | -78.65M | -78.04M | -62.85M | -85.80M | -59.12M | -61.92M | -43.33M |
| Interest Expense | 11.84M | 13.58M | 11.34M | 7.02M | 6.67M | 6.77M | 6.10M | 1.74M | 1.89M | 1.68M |
| Other Income (Expense) | 4.08M | -21.73M | 1.65M | 7.62M | 71.48M | -92.79M | -570.00K | -860.00K | -1.46M | -1.38M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -265.94M | -193.51M | -80.74M | -71.04M | -6.55M | -155.64M | -86.37M | -59.98M | -63.39M | -44.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.42 | -1.22 | -1.01 | -0.92 | -0.09 | -2.56 | -1.91 | -1.57 | -2.20 | -1.80 |
| EPS (Diluted) | -1.42 | -1.22 | -1.02 | -0.97 | -0.98 | -2.56 | -1.91 | -1.57 | -2.20 | -1.80 |
| Shares Outstanding (Basic) | 187.24M | 158.27M | 79.83M | 76.88M | 76.39M | 60.75M | 45.27M | 38.12M | 28.82M | 24.82M |
| Shares Outstanding (Diluted) | 187.24M | 158.27M | 85.60M | 82.64M | 82.16M | 60.75M | 45.27M | 38.12M | 28.82M | 24.82M |
| EBITDA | -265.69M | -168.00M | -79.40M | -76.55M | -75.62M | -60.07M | -83.27M | -56.83M | -60.30M | -42.45M |
| Gross Margin | 87.35% | 91.17% | 90.96% | 91.18% | 89.88% | 88.03% | 45.00% | 76.63% | 76.24% | 76.52% |
| Operating Margin | -519.75% | -269.57% | -140.96% | -152.74% | -179.30% | -361.13% | -2029.86% | -2970.75% | -3220.12% | -2296.03% |
| Net Margin | -511.90% | -303.67% | -138.14% | -137.95% | -15.06% | -894.31% | -2043.34% | -3013.97% | -3296.20% | -2369.00% |
This table shows 10 annual periods of Ocular Therapeutix's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow OCUL's reporting calendar. What is a income statement?